YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a...
Hence then, the article about gc biopharma secures cmo rights for shingles vaccine from curevo vaccine was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine )
Also on site :
- Here’s how 2025 killed old-school diplomacy
- Quantum Computing in Financial Services Market Set to Reach USD 6.3 Billion by 2032 as Banks Move from Experimentation to Quantum Advantage .. DataM Intelligence
- The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million